Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib in Advanced Solid Tumors With FGFR Alteration
NCT03929965Unknown
- Sponsor
- Shanghai Changzheng Hospital
- Start
- Jul 2019
- Primary completion
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of anlotinib in solid tumor (advanced stage), sponsored by Shanghai Changzheng Hospital. Primary endpoint: Objective Response Rate at 36 months. Status: unknown.
02
Drugs
anlotinib
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT03929965.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03929965.